Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Katherine Ludington

Cardiovascular Disease Encinitas, CA Medical Doctor

NPI 1164420469 CMS profile 7667

4401 Manchester Ave, Suite 103, Encinitas, CA 92024

Open in the dashboard

General payments

$8,033

304 records reported · program years 2019–2025

Research payments

$93,288

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$491,998 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Katherine Ludington of Encinitas, CA is reported in the CMS Open Payments database as having received $8,033 across 304 general payments and $93,288 in research payments paid to them. Separately, studies naming them as principal investigator received $491,998 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,149 41
2025 Research $676 1
2024 General $1,533 42
2024 Research $92,612 2
2023 General $689 28
2022 General $1,223 32
2021 General $1,201 55
2020 General $648 22
2019 General $1,590 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Ludington
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Katherine Ludington were reported at $1,149. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Katherine Ludington Cardiovascular Disease median Middle half National median
2019 $1,590 $450 $127–$1,392 $163
2020 $648 $242 $77–$751 $114
2021 $1,201 $335 $101–$1,037 $132
2022 $1,223 $395 $121–$1,211 $149
2023 $689 $443 $136–$1,283 $160
2024 $1,533 $450 $136–$1,323 $164
2025 $1,149 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $1,761 34 payments
  2. Impulse Dynamics (USA) Inc. $1,477 32 payments
  3. Medtronic, Inc. $892 23 payments
  4. Pfizer Inc. $375 47 payments
  5. Abbott Laboratories $370 12 payments
  6. Amgen Inc. $318 17 payments
  7. Boston Scientific Corporation $274 11 payments
  8. E.R. Squibb & Sons, L.L.C. $241 12 payments
  9. Currax Pharmaceuticals LLC $236 15 payments
  10. Kowa Pharmaceuticals America, Inc. $182 12 payments
  11. Other $1,908 89 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,014 303 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. OPTIMIZER Cardiovascular Device $1,477 32 payments
  2. OPTIMIZER Cardiovascular Device $1,477 32 payments
  3. LINQ II $879 22 payments
  4. BioMonitor $772 12 payments
  5. ELIQUIS $375 47 payments
  6. Rivacor $364 6 payments
  7. Solia $364 6 payments
  8. Edora $364 6 payments
  9. Acticor $364 6 payments
  10. Repatha $249 13 payments
  11. Other $3,684 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $93,288 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

3,495

Median for Cardiology: 2,533

Drug cost

$674,177

Median for Cardiology: $485,213

Branded share of claims

31.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 245 $322,649
Xarelto Rivaroxaban Brand 90 $129,539
Repatha Sureclick Evolocumab Brand 41 $49,103
Praluent Pen Alirocumab Brand 64 $46,972
Livalo Pitavastatin Calcium Brand 24 $18,750
Entresto Sacubitril/Valsartan Brand 16 $15,870
Mounjaro Tirzepatide Brand 11 $12,364
Rosuvastatin Calcium Generic 535 $8,383
Metoprolol Succinate Generic 361 $6,769
Propafenone Hcl Er Propafenone Hcl Brand 21 $5,858

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$1,191,379

Of which drugs: $32,653

Medicare patients

864

Average age 76

Services billed

13,461

578 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 36%
Atrial fibrillation 33%
Heart failure 27%
Diabetes 20%
Chronic kidney disease 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 142 177 $26,344
Injection, regadenoson, 0.1 mg J2785 Office 167 664 $3,409
Sarscv2 vac 30mcg trs-suc im 91320 Office 17 17 $2,573

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $86
$86 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $60
$60 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $41
$41 — —
Repatha
  • Amgen Inc. $23
$23 41 —
CONTRAVE
  • Currax Pharmaceuticals LLC $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

307 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record